Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in improving overall survival of several malignancies associated with poor outcomes; however, only 20–40% of patients will show long-lasting survival. Further clarification of factors related to treatment response can...

Descripción completa

Detalles Bibliográficos
Autores principales: Centanni, Maddalena, Moes, Dirk Jan A. R., Trocóniz, Iñaki F., Ciccolini, Joseph, van Hasselt, J. G. Coen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584248/
https://www.ncbi.nlm.nih.gov/pubmed/30815848
http://dx.doi.org/10.1007/s40262-019-00748-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584248/
https://www.ncbi.nlm.nih.gov/pubmed/30815848
http://dx.doi.org/10.1007/s40262-019-00748-2

Ejemplares similares